Livforsakringsbolaget Skandia’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $596K | Hold |
772
| – | – | 0.02% | 200 |
|
|
2025
Q4 | $596K | Hold |
772
| – | – | 0.02% | 212 |
|
|
2025
Q3 | $434K | Sell |
772
-100
| -11% | -$56.5K | 0.02% | 263 |
|
|
2025
Q2 | $457K | Sell |
872
-10,460
| -92% | -$5.84M | 0.02% | 265 |
|
|
2025
Q1 | $7.18M | Hold |
11,332
| – | – | 0.41% | 63 |
|
|
2024
Q4 | $8.07M | Sell |
11,332
-100
| -0.9% | -$83.9K | 0.43% | 60 |
|
|
2024
Q3 | $12M | Buy |
11,432
+2,900
| +34% | +$3.23M | 0.65% | 35 |
|
|
2024
Q2 | $8.97M | Sell |
8,532
-100
| -1% | -$96.9K | 0.73% | 29 |
|
|
2024
Q1 | $8.3M | Hold |
8,632
| – | – | 0.7% | 37 |
|
|
2023
Q4 | $7.58M | Buy |
8,632
+118
| +1% | +$97.2K | 0.72% | 32 |
|
|
2023
Q3 | $7M | Sell |
8,514
-400
| -4% | -$314K | 0.77% | 35 |
|
|
2023
Q2 | $6.4M | Sell |
8,914
-900
| -9% | -$694K | 0.66% | 43 |
|
|
2023
Q1 | $8.06M | Hold |
9,814
| – | – | 0.84% | 28 |
|
|
2022
Q4 | $7.08M | Sell |
9,814
-22
| -0.2% | -$16.2K | 0.81% | 33 |
|
|
2022
Q3 | $6.78M | Sell |
9,836
-1,700
| -15% | -$1.07M | 0.84% | 29 |
|
|
2022
Q2 | $6.82M | Sell |
11,536
-200
| -2% | -$130K | 0.59% | 43 |
|
|
2022
Q1 | $8.2M | Hold |
11,736
| – | – | 0.55% | 44 |
|
|
2021
Q4 | $7.41M | Buy |
11,736
+1,820
| +18% | +$1.12M | 0.47% | 52 |
|
|
2021
Q3 | $6M | Buy |
9,916
+2,610
| +36% | +$1.62M | 0.37% | 67 |
|
|
2021
Q2 | $4.08M | Buy |
7,306
+400
| +6% | +$203K | 0.24% | 94 |
|
|
2021
Q1 | $3.27M | Buy |
6,906
+800
| +13% | +$389K | 0.23% | 102 |
|
|
2020
Q4 | $2.95M | Buy |
6,106
+600
| +11% | +$324K | 0.25% | 90 |
|
|
2020
Q3 | $3.08M | Buy |
5,506
+560
| +11% | +$340K | 0.33% | 71 |
|
|
2020
Q2 | $3.08M | Buy |
4,946
+1,870
| +61% | +$1.06M | 0.35% | 68 |
|
|
2020
Q1 | $1.5M | Buy |
3,076
+300
| +11% | +$124K | 0.21% | 107 |
|
|
2019
Q4 | $1.04M | Sell |
2,776
-400
| -13% | -$135K | 0.12% | 154 |
|
|
2019
Q3 | $881K | Buy |
3,176
+800
| +34% | +$237K | 0.1% | 173 |
|
|
2019
Q2 | $743K | Buy |
2,376
+1,600
| +206% | +$533K | 0.09% | 182 |
|
|
2019
Q1 | $319K | Buy |
776
+100
| +15% | +$41.2K | 0.04% | 286 |
|
|
2018
Q4 | $252K | Hold |
676
| – | – | 0.04% | 293 |
|
|
2018
Q3 | $273K | Sell |
676
-800
| -54% | -$304K | 0.03% | 335 |
|
|
2018
Q2 | $509K | Buy |
1,476
+300
| +26% | +$93.8K | 0.05% | 323 |
|
|
2018
Q1 | $405K | Hold |
1,176
| – | – | 0.04% | 341 |
|
|
2017
Q4 | $442K | Sell |
1,176
-300
| -20% | -$122K | 0.04% | 332 |
|
|
2017
Q3 | $660K | Hold |
1,476
| – | – | 0.06% | 296 |
|
|
2017
Q2 | $725K | Hold |
1,476
| – | – | 0.07% | 270 |
|
|
2017
Q1 | $572K | Sell |
1,476
-2,800
| -65% | -$1.04M | 0.05% | 308 |
|
|
2016
Q4 | $1.57K | Sell |
4,276
-69,424
| -94% | -$26.4M | 0.08% | 265 |
|
|
2016
Q3 | $2.79M | Buy |
73,700
+67,024
| +1,004% | +$26.9M | 0.14% | 203 |
|
|
2016
Q2 | $2.33M | Hold |
6,676
| – | – | 0.1% | 231 |
|
|
2016
Q1 | $2.41M | Sell |
6,676
-1,500
| -18% | -$618K | 0.11% | 203 |
|
|
2015
Q4 | $4.44M | Buy |
8,176
+900
| +12% | +$488K | 0.21% | 109 |
|
|
2015
Q3 | $3.38M | Hold |
7,276
| – | – | 0.18% | 120 |
|
|
2015
Q2 | $3.71M | Hold |
7,276
| – | – | 0.18% | 116 |
|
|
2015
Q1 | $3.29M | Sell |
7,276
-1,700
| -19% | -$720K | 0.16% | 131 |
|
|
2014
Q4 | $3.68M | Sell |
8,976
-2,500
| -22% | -$983K | 0.17% | 133 |
|
|
2014
Q3 | $4.14M | Hold |
11,476
| – | – | 0.16% | 147 |
|
|
2014
Q2 | $3.24M | Hold |
11,476
| – | – | 0.12% | 193 |
|
|
2014
Q1 | $3.45M | Buy |
+11,476
| New | +$3.54M | 0.13% | 180 |
|
Other funds holding REGN
VCM
N
Livforsakringsbolaget Skandia's REGN Position: Q1 2026 in Review
Livforsakringsbolaget Skandia held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 772 shares worth $596K. The position accounts for 0.02% of the portfolio, ranked #200.
Livforsakringsbolaget Skandia first reported a position in REGN in Q1 2014 and has held it in 49 quarters since. The position peaked at $12M in Q3 2024. 1,397 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Livforsakringsbolaget Skandia held 772 shares of Regeneron Pharmaceuticals worth $596K as of Q1 2026.
- Livforsakringsbolaget Skandia left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
- Regeneron Pharmaceuticals made up 0.02% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #200 holding.
- Livforsakringsbolaget Skandia first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- Livforsakringsbolaget Skandia's Regeneron Pharmaceuticals position peaked at $12M in Q3 2024.
- 1,397 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.